Belgium· BE-AMP-SAM494097-00
Portrazza 800 mg
A necitumumab product containing necitumumab, registered in Belgium by Eli Lilly Nederland. The same ATC class is registered in 5 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Necitumumab is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FE03 (necitumumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 2 of them publish a price we can compare per daily dose
Necitumumab · ATC L01FE03
5 / 19 countries
- Belgiumprice
- Denmark
- Finlandprice
- Netherlands
- United Kingdom
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Necitumumab
- Manufacturer
- Eli Lilly Nederland
- Country
- Belgium (BE)
- ATC code
- L01FE03
- ATC class
- Necitumumab
- Defined daily dose
- 76 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for necitumumab.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Necitumumab · interactions on record
5 records
- 1 severe
- 3 moderate
- 1 minor
Most severe, free to view
- ThalidomideL04AX02severe
- IdelalisibL01EM01moderate
- IdelalisibL01XX47moderate
- PaliferminV03AF08moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Necitumumab in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandPortrazzaEli Lilly Nederland B.V.
- United KingdomPortrazza 800mg/50ml concentrate for solution for infusion vialsEli Lilly and Company Ltd
- SpainPORTRAZZA 800mg concentrado para solucion para perfusionEli Lilly Nederland B.V.
- Japanネシツムマブ（遺伝子組換え）日本化薬
- NetherlandsPortrazza, concentraat voor oplossing voor infusieEli Lilly Nederland BV
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6281ed6e-63c0-421d-86f2-5d0dcd981450 GET /v1/drugs/6281ed6e-63c0-421d-86f2-5d0dcd981450?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "REVOKED",
"name_en": "Portrazza 800 mg",
"name_fr": "Portrazza 800 mg",
"name_nl": "Portrazza 800 mg",
"amp_code": "SAM494097-00",
"strengths": [
"16.0000",
"16.0000",
"76.0000"
],
"pack_count": 1,
"substances": [
"Necitumumab",
"Mannitol",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Necitumumab",
"authorisation_numbers": [
"EU/1/15/1084/001"
]
}See everything about necitumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.